{"url_path":"/sec/anvs/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1477845/0001104659-26-062626-index.html","accession_number":"0001104659-26-062626","cik":"0001477845","ticker":"ANVS","issuer_name":"Annovis Bio, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1477845/0001104659-26-062626-index.html","primary_entity_key":"0001477845","primary_entity_name":"Annovis Bio, Inc."},"word_count":787,"has_tables":true,"body_markdown":"Annovis Bio, Inc._MARCH 31, 2026\n\nNon-accelerated Filer000001477845--12-312026Q1false000.000100271991392853730211 Other segment items included in net loss include insurance expenses, rent expense, information technology expenses, listing/printing fees, warrant commissions and other miscellaneous expenses. 2 Other non-cash income (expense) items include the change in fair value of our liability classified warrants.P5YP5Y6M0001477845anvs:WarrantsClassifiedAsLiabilitiesMember2023-11-030001477845anvs:WarrantsClassifiedAsLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputSharePriceMember2026-03-310001477845anvs:WarrantsClassifiedAsLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRiskFreeInterestRateMember2026-03-310001477845anvs:WarrantsClassifiedAsLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputPriceVolatilityMember2026-03-310001477845anvs:WarrantsClassifiedAsLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedTermMember2026-03-310001477845anvs:WarrantsClassifiedAsLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExercisePriceMember2026-03-310001477845anvs:WarrantsClassifiedAsLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputSharePriceMember2025-12-310001477845anvs:WarrantsClassifiedAsLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRiskFreeInterestRateMember2025-12-310001477845anvs:WarrantsClassifiedAsLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputPriceVolatilityMember2025-12-310001477845anvs:WarrantsClassifiedAsLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedTermMember2025-12-310001477845anvs:WarrantsClassifiedAsLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExercisePriceMember2025-12-310001477845anvs:PlacementAgentWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2025-10-260001477845anvs:PlacementAgentWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2025-10-260001477845anvs:PlacementAgentWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2025-10-260001477845anvs:PlacementAgentWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2025-10-260001477845anvs:PlacementAgentWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2025-10-140001477845anvs:PlacementAgentWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2025-10-140001477845anvs:PlacementAgentWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2025-10-140001477845anvs:PlacementAgentWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2025-10-140001477845anvs:RegisteredDirectOfferingMember2026-03-310001477845anvs:StockSubscriptionAgreementsMember2025-10-262025-10-260001477845anvs:SecuritiesPurchaseAgreementMember2025-10-262025-10-260001477845us-gaap:RetainedEarningsMember2026-03-310001477845us-gaap:AdditionalPaidInCapitalMember2026-03-310001477845us-gaap:RetainedEarningsMember2025-12-310001477845us-gaap:AdditionalPaidInCapitalMember2025-12-310001477845us-gaap:RetainedEarningsMember2025-03-310001477845us-gaap:AdditionalPaidInCapitalMember2025-03-310001477845us-gaap:RetainedEarningsMember2024-12-310001477845us-gaap:AdditionalPaidInCapitalMember2024-12-310001477845us-gaap:CommonStockMember2026-03-310001477845us-gaap:CommonStockMember2025-12-310001477845us-gaap:CommonStockMember2025-03-310001477845us-gaap:CommonStockMember2024-12-310001477845anvs:RegisteredDirectOfferingMember2025-10-2600014778452025-01-012025-12-310001477845anvs:EquityIncentivePlan2019Member2026-03-310001477845anvs:EquityIncentivePlan2018Member2026-03-310001477845anvs:EquityIncentivePlan2019Member2024-06-120001477845anvs:EquityIncentivePlan2019Member2021-06-010001477845anvs:EquityIncentivePlan2019Member2020-01-310001477845us-gaap:EmployeeStockOptionMember2026-01-012026-03-310001477845us-gaap:RestrictedStockMember2025-01-012025-03-3100014778452026-03-012026-03-310001477845us-gaap:SubsequentEventMemberanvs:AtMarketOfferingMember2026-04-012026-04-300001477845anvs:October2023CanaccordEquityOfferingAndWarrantIssuanceMember2023-10-312023-10-310001477845anvs:RegisteredDirectOfferingMember2025-10-262025-10-260001477845anvs:RegisteredDirectOfferingMember2025-10-102025-10-100001477845us-gaap:RetainedEarningsMember2026-01-012026-03-310001477845us-gaap:RetainedEarningsMember2025-01-012025-03-310001477845us-gaap:WarrantMember2026-01-012026-03-310001477845anvs:WarrantsClassifiedAsLiabilitiesMember2026-01-012026-03-310001477845anvs:WarrantsClassifiedAsLiabilitiesMemberus-gaap:FairValueInputsLevel3Member2026-03-310001477845anvs:WarrantsClassifiedAsLiabilitiesMemberus-gaap:FairValueInputsLevel3Member2025-12-310001477845anvs:WarrantsClassifiedAsLiabilitiesExpirationNovember22028Member2025-12-310001477845anvs:ThinkEquityWarrantsExpirationFebruary42030Member2025-12-310001477845anvs:PlacementAgentWarrantsExpirationOctober202030Member2025-12-310001477845anvs:PlacementAgentWarrantsExpirationOctober142030Member2025-12-310001477845anvs:WarrantsClassifiedAsLiabilitiesExpirationNovember22028Member2026-03-310001477845anvs:ThinkEquityWarrantsExpirationFebruary42030Member2026-03-310001477845anvs:PlacementAgentWarrantsExpirationOctober202030Member2026-03-310001477845anvs:PlacementAgentWarrantsExpirationOctober142030Member2026-03-310001477845anvs:PlacementAgentWarrantsMember2025-10-260001477845anvs:PlacementAgentWarrantsMember2025-10-140001477845anvs:ThinkEquityWarrantsMemberanvs:February2025ThinkEquityUnderwrittenOfferingAndWarrantIssuanceMember2025-02-030001477845anvs:WarrantsClassifiedAsLiabilitiesMember2023-10-310001477845anvs:October2023CanaccordEquityOfferingAndWarrantIssuanceMember2023-10-3100014778452025-03-3100014778452024-12-310001477845us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2026-03-310001477845us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2025-12-310001477845us-gaap:WarrantMember2026-01-012026-03-310001477845us-gaap:EmployeeStockOptionMember2026-01-012026-03-310001477845us-gaap:WarrantMember2025-01-012025-03-310001477845us-gaap:RestrictedStockMember2025-01-012025-03-310001477845us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001477845us-gaap:ResearchAndDevelopmentExpenseMember2026-01-012026-03-310001477845us-gaap:GeneralAndAdministrativeExpenseMember2026-01-012026-03-310001477845us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-03-310001477845us-gaap:GeneralAndAdministrativeExpenseMember2025-01-012025-03-3100014778452026-05-150001477845us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2026-03-310001477845us-gaap:CarryingReportedAmountFairValueDisclosureMember2026-03-310001477845anvs:WarrantsClassifiedAsLiabilitiesMember2026-03-310001477845us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2025-12-310001477845us-gaap:CarryingReportedAmountFairValueDisclosureMember2025-12-310001477845anvs:WarrantsClassifiedAsLiabilitiesMember2025-12-310001477845anvs:RegisteredDirectOfferingMember2025-01-012025-12-310001477845anvs:WarrantsClassifiedAsEquityMember2020-01-290001477845anvs:WarrantsClassifiedAsEquityMember2020-01-292020-01-290001477845us-gaap:SubsequentEventMemberanvs:UnderwritingAgreementMember2026-04-090001477845anvs:February2025ThinkEquityUnderwrittenOfferingAndWarrantIssuanceMember2025-02-030001477845us-gaap:SubsequentEventMemberanvs:UnderwritingAgreementMember2026-04-092026-04-090001477845anvs:February2025ThinkEquityUnderwrittenOfferingAndWarrantIssuanceMember2025-02-032025-02-030001477845anvs:December2024AtMarketEquityOfferingMember2026-01-012026-03-310001477845anvs:December2024AtMarketEquityOfferingMember2025-01-012025-03-310001477845anvs:SingleReportableSegmentMember2026-01-012026-03-310001477845anvs:SingleReportableSegmentMember2025-01-012025-03-310001477845us-gaap:CommonStockMember2026-01-012026-03-310001477845us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001477845us-gaap:CommonStockMember2025-01-012025-03-310001477845us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-3100014778452025-01-012025-03-310001477845anvs:WarrantsClassifiedAsLiabilitiesExpirationNovember22028Member2026-01-012026-03-310001477845anvs:ThinkEquityWarrantsExpirationFebruary42030Member2026-01-012026-03-310001477845anvs:PlacementAgentWarrantsExpirationOctober202030Member2026-01-012026-03-310001477845anvs:PlacementAgentWarrantsExpirationOctober142030Member2026-01-012026-03-310001477845anvs:RegisteredDirectOfferingMember2025-10-100001477845anvs:WarrantsClassifiedAsLiabilitiesMemberanvs:October2023CanaccordEquityOfferingAndWarrantIssuanceMember2026-01-012026-03-310001477845anvs:ThinkEquityWarrantsMemberanvs:February2025ThinkEquityUnderwrittenOfferingAndWarrantIssuanceMember2026-01-012026-03-3100014778452026-01-012026-03-310001477845anvs:WarrantsClassifiedAsLiabilitiesMemberanvs:October2023CanaccordEquityOfferingAndWarrantIssuanceMember2025-01-012025-03-310001477845anvs:December2024AtMarketEquityOfferingMember2024-12-1100014778452026-03-3100014778452025-12-31iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesanvs:itemanvs:leaseanvs:Votexbrli:pureanvs:segmentanvs:Y\n\n[Table of Contents](#TOC)\n\n​\n\n​\n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**WASHINGTON, D.C. 20549**\n\n**FORM ****10-Q**\n\n​\n\n​\n\n​\n\n☒\n\n**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n​\n\n**FOR THE QUARTERLY PERIOD ENDED****MARCH 31, 2026**\n\n**OR**\n\n​\n\n​\n\n☐\n\n**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n​\n\n**COMMISSION FILE NUMBER****001-39202**\n\n**Annovis Bio, Inc.**\n\n(Exact name of registrant as specified in its charter)\n\n**Delaware**\n\n​\n\n**26-2540421**\n\n(State or other jurisdiction of\nincorporation or organization)\n\n​\n\n(I.R.S. Employer\nIdentification No.)\n\n​\n\n**101 Lindenwood Drive, Suite 225**\n\n**Malvern****,****PA********19355**\n\n(Address of registrant’s principal executive offices)\n\n**(****484****) ****875-3192**\n\nRegistrant’s telephone number, including area code\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n​\n\n**Title of Each Class**\n\n  ​ ​ ​\n\n**Trading Symbol**\n\n  ​ ​ ​\n\n**Name of Each Exchange on Which Registered**\n\nCommon Stock, par value $0.0001 per share\n\n​\n\nANVS\n\n​\n\nNew York Stock Exchange\n\n​\n\nIndicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No.\n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No.\n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n​\n\nLarge accelerated filer\n\n☐\n\n​\n\nAccelerated filer\n\n☐\n\n​\n\n​\n\n​\n\n​\n\n​\n\nNon-accelerated filer\n\n☒\n\n​\n\nSmaller reporting company\n\n☒\n\n​\n\n​\n\n​\n\n​\n\n​\n\nEmerging growth company\n\n☐\n\n​\n\n​\n\n​\n\n​\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No.\n\nThe number of outstanding shares of the registrant’s common stock as of May 15, 2026 was: 34,646,868\n\n​\n\n​\n\n​\n\n​\n\n[Table of Contents](#TOC)\n\nANNOVIS BIO, INC.\n\nQUARTERLY REPORT ON FORM 10-Q\n\nFOR THE QUARTER ENDED MARCH 31, 2026\n\n​\n\n[**PART I – FINANCIAL INFORMATION**](#PARTI_259670)\n\n  ​ ​\n\nPage\n\n​\n\n​\n\n​\n\n​\n\n​\n\n[Item 1.](#Item1FinancialStatements_370734)\n\n[Financial Statements](#Item1FinancialStatements_370734)\n\n​\n\n3\n\n​\n\n​\n\n​\n\n​\n\n[Balance Sheets as of March 31, 2026 (Unaudited) and December 31, 2025](#BalanceSheets_395467)\n\n​\n\n3\n\n​\n\n​\n\n​\n\n​\n\n[Statements of Operations (Unaudited) for the Three Months Ended March 31, 2026 and 2025](#StatementsofOperations_512905)\n\n​\n\n4\n\n​\n\n​\n\n​\n\n​\n\n[Statements of Changes in Stockholders’ Equity (Unaudited) for the Three Months Ended March 31, 2026 and 2025](#Eqity_Table)\n\n​\n\n5\n\n​\n\n​\n\n​\n\n​\n\n[Statements of Cash Flows (Unaudited) for the Three Months Ended March 31, 2026 and 2025](#StatementsofCashFlows_949453)\n\n​\n\n6\n\n​\n\n​\n\n​\n\n​\n\n[Notes to Financial Statements (Unaudited)](#Notes_97879)\n\n​\n\n7\n\n​\n\n​\n\n​\n\n​\n\n[Item 2.](#Item2ManagementsDiscussionandAnalysis_12)\n\n[Management’s Discussion and Analysis of Financial Condition and Results of Operations](#Item2ManagementsDiscussionandAnalysis_12)\n\n​\n\n20\n\n​\n\n​\n\n​\n\n​\n\n[Item 3.](#Item3QuantitativeandQualitativeDisclosur)\n\n[Quantitative and Qualitative Disclosure About Market Risk](#Item3QuantitativeandQualitativeDisclosur)\n\n​\n\n29\n\n​\n\n​\n\n​\n\n​\n\n[Item 4.](#Item4ControlsandProcedures_736580)\n\n[Controls and Procedures](#Item4ControlsandProcedures_736580)\n\n​\n\n30\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n[**PART II – OTHER INFORMATION**](#PARTII_497958)\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n[Item 1.](#Item1LegalProceedings_902802)\n\n[Legal Proceedings](#Item1LegalProceedings_902802)\n\n​\n\n31\n\n​\n\n​\n\n​\n\n​\n\n[Item 1A.](#Item1ARiskFactors_168603)\n\n[Risk Factors](#Item1ARiskFactors_168603)\n\n​\n\n31\n\n​\n\n​\n\n​\n\n​\n\n[Item 2.](#Item2UnregisteredSalesofEquitySecurities)\n\n[Unregistered Sales of Equity Securities and Use of Proceeds](#Item2UnregisteredSalesofEquitySecurities)\n\n​\n\n31\n\n​\n\n​\n\n​\n\n​\n\n[Item 3.](#Item3DefaultsuponSeniorSecurities_659897)\n\n[Defaults Upon Senior Securities](#Item3DefaultsuponSeniorSecurities_659897)\n\n​\n\n31\n\n​\n\n​\n\n​\n\n​\n\n[Item 4.](#Item4MineSafetyDisclosures_771828)\n\n[Mine Safety Disclosures](#Item4MineSafetyDisclosures_771828)\n\n​\n\n31\n\n​\n\n​\n\n​\n\n​\n\n[Item 5.](#Item5OtherInformation_63889)\n\n[Other Information](#Item5OtherInformation_63889)\n\n​\n\n31\n\n​\n\n​\n\n​\n\n​\n\n[Item 6.](#Item6Exhibits)\n\n[Exhibits](#Item6Exhibits)\n\n​\n\n32\n\n​\n\n​\n\n​\n\n​\n\n[Signatures](#SIGNATURES_418031)\n\n​\n\n34\n\n​\n\n​\n\n​\n\n2\n\n[Table of Contents](#TOC)\n\nPART I\n\nFINANCIAL INFORMATION"}